New Strategy for the Generation of Specific d-Peptide Amyloid Inhibitors

Journal of Molecular Biology

Volumn 377, Issue 5, 2008, Pages 1372-1381

  Esteras Chopo, Alexandra ^a   Pastor, M Teresa ^a   Serrano, Luis ^a   López de la Paz, Manuela ^a  

^a EUROPEAN MOLECULAR BIOLOGY LABORATORY   (Germany)

Author keywords

amyloid inhibition; amyloid toxicity inhibition; amyloidoses; d peptides; general strategy

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; AMYLOID INHIBITOR; AMYLOID PROTEIN; PEPTIDE LIBRARY; PROTEIN INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CHIRALITY; CIRCULAR DICHROISM; CONTROLLED STUDY; CYTOTOXICITY; DRUG DESIGN; DRUG SCREENING; ELECTRON MICROSCOPY; NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 40949089587     PISSN: 00222836     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jmb.2008.01.028     Document Type: Article

References (48)

1. Ross C.A., and Poirier M.A. Protein aggregation and neurodegenerative disease. Nat. Med. 10 (2004) S10-S17
2. Citron M. Strategies for disease modification in Alzheimer's disease. Nat. Rev. Neurosci. 5 (2004) 677-685
3. Soto C. Unfolding the role of protein misfolding in neurodegenerative diseases. Nat. Rev. Neurosci. 4 (2003) 49-60
4. Mason J.M., Kokkoni N., Stott K., and Doig A.J. Design strategies for anti-amyloid agents. Curr. Opin. Struct. Biol. 13 (2003) 526-532
5. Talaga P. Beta-amyloid aggregation inhibitors for the treatment of Alzheimer's disease: dream or reality?. Mini Rev. Med. Chem. 1 (2001) 175-186
6. LeVine H. The challenge of inhibiting Abeta polymerization. Curr. Med. Chem. 9 (2002) 1121-1133
7. Petrassi H.M., Johnson S.M., Purkey H.E., Chiang K.P., Walkup T., Jiang X., et al. Potent and selective structure-based dibenzofuran inhibitors of transthyretin amyloidogenesis: kinetic stabilization of the native state. J. Am. Chem. Soc. 127 (2005) 6662-6671
8. Kocisko D.A., Baron G.S., Rubenstein R., Chen J., Kuizon S., and Caughey B. New inhibitors of scrapie-associated prion protein formation in a library of 2000 drugs and natural products. J. Virol. 77 (2003) 10288-10294
9. Lin Y.M., Raffen R., Zhou Y., Cassidy C.S., Flavin M.T., and Stevens F.J. Amyloid fibril formation in microwell plates for screening of inhibitors. Amyloid 8 (2001) 182-193
10. Esteras-Chopo A., Pastor M.T., and López de la Paz M. Peptide model systems for amyloid fiber formation: design strategies and validation methods. Methods Mol. Biol. 340 (2006) 253-276
11. Hughes E., Burke R.M., and Doig A.J. Inhibition of toxicity in the beta-amyloid peptide fragment β(25-35) using N-methylated derivatives-a general strategy to prevent amyloid formation. J. Biol. Chem. 275 (2000) 25109-25115
12. Kapurniotu A., Schmauder A., and Tenidis K. Structure-based design and study of non-amyloidogenic, double N-methylated IAPP amyloid core sequences as inhibitors of IAPP amyloid formation and cytotoxicity. J. Mol. Biol. 315 (2002) 339-350
13. Findeis M.A., Musso G.M., Arico-Muendel C.C., Benjamin H.W., Hundal A.M., Lee J.J., et al. Modified-peptide inhibitors of amyloid beta-peptide polymerization. Biochemistry 38 (1999) 6791-6800
14. Soto C., Kindy M.S., Baumann M., and Frangione B. Inhibition of Alzheimer's amyloidosis by peptides that prevent beta-sheet conformation. Biochem. Biophys. Res. Commun. 226 (1996) 672-680
15. Gilead S., and Gazit E. Inhibition of amyloid fibril formation by peptide analogues modified with alpha-aminoisobutyric acid. Angew. Chem., Int. Ed. Engl. 43 (2004) 4041-4044
16. Gibson T.J., and Murphy R.M. Inhibition of insulin fibrillogenesis with targeted peptides. Protein Sci. 15 (2006) 1133-1141
17. Lowe T.L., Strzelec A., Kiessling L.L., and Murphy R.M. Structure-function relationships for inhibitors of beta-amyloid toxicity containing the recognition sequence KLVFF. Biochemistry 40 (2001) 7882-7889
18. Permanne B., Adessi C., Saborio G.P., Fraga S., Frossard M.J., Van Dorpe J., et al. Reduction of amyloid load and cerebral damage in a transgenic mouse model of Alzheimer's disease by treatment with a beta-sheet breaker peptide. FASEB J. 16 (2002) 860-862
19. Adessi C., Frossard M.J., Boissard C., Fraga S., Bieler S., Ruckle T., et al. Pharmacological profiles of peptide drug candidates for the treatment of Alzheimer's disease. J. Biol. Chem. 278 (2003) 13905-13911
20. Soto-Jara, C., Baumann, M. H. & Frangione, B. (2002). Peptides and pharmaceutical compositions thereof for treatment of disorders or diseases associated with abnormal protein folding into amyloid or amyloid-like deposits. US Patent 6462171.
21. Chacon M.A., Barria M.I., Soto C., and Inestrosa N.C. Beta-sheet breaker peptide prevents Abeta-induced spatial memory impairments with partial reduction of amyloid deposits. Mol. Psychiatry 9 (2004) 953-961
22. Axonyx Announces Milestone Payment from Serono after Initiation of Clinical Trial in Alzheimer's. Press release (April 14, 2003): http://findarticles.com/p/articles/mi_m0EIN/is_2003_April_24/ai_10054655 1
23. Tjernberg L.O., Lilliehook C., Callaway D.J., Naslund J., Hahne S., Thyberg J., et al. Controlling amyloid beta-peptide fibril formation with protease-stable ligands. J. Biol. Chem. 272 (1997) 12601-12605
24. Chalifour R.J., McLaughlin R.W., Lavoie L., Morissette C., Tremblay N., Boule M., et al. Stereoselective interactions of peptide inhibitors with the beta-amyloid peptide. J. Biol. Chem. 278 (2003) 34874-34881
25. Wiesehan K., Buder K., Linke R.P., Patt S., Stoldt M., Unger E., et al. Selection of d-amino-acid peptides that bind to Alzheimer's disease amyloid peptide abeta1-42 by mirror image phage display. ChemBioChem 4 (2003) 748-753
26. Blanchard B.J., Konopka G., Russell M., and Ingram V.M. Mechanism and prevention of neurotoxicity caused by beta-amyloid peptides: relation to Alzheimer's disease. Brain Res. 776 (1997) 40-50
27. Esler W.P., Stimson E.R., Fishman J.B., Ghilardi J.R., Vinters H.V., Mantyh P.W., and Maggio J.E. Stereochemical specificity of Alzheimer's disease beta-peptide assembly. Biopolymers 49 (1999) 505-514
28. Wadai H., Yamaguchi K., Takahashi S., Kanno T., Kawai T., Naiki H., and Goto Y. Stereospecific amyloid-like fibril formation by a peptide fragment of beta2-microglobulin. Biochemistry 44 (2005) 157-164
29. López de la Paz M., and Serrano L. Sequence determinants of amyloid fibril formation. Proc. Natl Acad. Sci. USA 101 (2004) 87-92
30. Esteras-Chopo A., Serrano L., and López de la Paz M. The amyloid stretch hypothesis: recruiting proteins toward the dark side. Proc. Natl Acad. Sci. USA 102 (2005) 16672-16677
31. Ventura S., Zurdo J., Narayanan S., Parreno M., Mangues R., Reif B., et al. Short amino acid stretches can mediate amyloid formation in globular proteins: the Src homology 3 (SH3) case. Proc. Natl Acad. Sci. USA 101 (2004) 7258-7263
32. Ivanova M.I., Sawaya M.R., Gingery M., Attinger A., and Eisenberg D. An amyloid-forming segment of beta2-microglobulin suggests a molecular model for the fibril. Proc. Natl Acad. Sci. USA 101 (2004) 10584-10589
33. Pastor M.T., Kummerer N., Schubert V., Esteras-Chopo A., Dotti C.G., López de la Paz M., and Serrano L. Amyloid toxicity is independent of polypeptide sequence, length and chirality. J. Mol. Biol. 375 (2008) 695-707
34. López de la Paz M., Goldie K., Zurdo J., Lacroix E., Dobson C.M., Hoenger A., and Serrano L. De novo designed peptide-based amyloid fibrils. Proc. Natl Acad. Sci. USA 99 (2002) 16052-16057
35. Bucciantini M., Calloni G., Chiti F., Formigli L., Nosi D., Dobson C.M., and Stefani M. Prefibrillar amyloid protein aggregates share common features of cytotoxicity. J. Biol. Chem. 279 (2004) 31374-31382
36. Cleary J.P., Walsh D.M., Hofmeister J.J., Shankar G.M., Kuskowski M.A., Selkoe D.J., and Ashe K.H. Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nat. Neurosci. 8 (2005) 79-84
37. Kayed R., Head E., Thompson J.L., McIntire T.M., Milton S.C., Cotman C.W., and Glabe C.G. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 300 (2003) 486-489
38. Walsh D.M., Klyubin I., Fadeeva J.V., Cullen W.K., Anwyl R., Wolfe M.S., et al. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416 (2002) 535-539
39. Pepys M.B. Pathogenesis, diagnosis and treatment of systemic amyloidosis. Philos. Trans. R. Soc. London, Ser. B 356 (2001) 203-210 discussion 210-1
40. Jimenez M.A., Munoz V., Rico M., and Serrano L. Helix stop and start signals in peptides and proteins. The capping box does not necessarily prevent helix elongation. J. Mol. Biol. 242 (1994) 487-496
41. Pastor M.T., López de la Paz M., Lacroix E., Serrano L., and Perez-Paya E. Combinatorial approaches: a new tool to search for highly structured beta-hairpin peptides. Proc. Natl Acad. Sci. USA 99 (2002) 614-619
42. Nelson R., Sawaya M.R., Balbirnie M., Madsen A.O., Riekel C., Grothe R., and Eisenberg D. Structure of the cross-beta spine of amyloid-like fibrils. Nature 435 (2005) 773-778
43. Fernandez-Escamilla A.M., Rousseau F., Schymkowitz J., and Serrano L. Prediction of sequence-dependent and mutational effects on the aggregation of peptides and proteins. Nat. Biotechnol. 22 (2004) 1302-1306
44. Pawar A.P., Dubay K.F., Zurdo J., Chiti F., Vendruscolo M., and Dobson C.M. Prediction of "aggregation-prone" and "aggregation-susceptible" regions in proteins associated with neurodegenerative diseases. J. Mol. Biol. 350 (2005) 379-392
45. Thompson M.J., Sievers S.A., Karanicolas J., Ivanova M.I., Baker D., and Eisenberg D. The 3D profile method for identifying fibril-forming segments of proteins. Proc. Natl Acad. Sci. USA 103 (2006) 4074-4078
46. Sawaya M.R., Sambashivan S., Nelson R., Ivanova M.I., Sievers S.A., Apostol M.I., et al. Atomic structures of amyloid cross-beta spines reveal varied steric zippers. Nature 447 (2007) 453-457
47. Goldsbury C., Frey P., Olivieri V., Aebi U., and Muller S.A. Multiple assembly pathways underlie amyloid-beta fibril polymorphisms. J. Mol. Biol. 352 (2005) 282-298
48. López de la Paz M., Lacroix E., Ramirez-Alvarado M., and Serrano L. Computer-aided design of beta-sheet peptides. J. Mol. Biol. 312 (2001) 229-246